Company Inga Prima Pharma Srl with Fiscal Code 28111360
recorded a turnover of 2024 of
40.108,
with a net profit of
11.719
and having an average number of employees of
1.
The company operates in the field of Facilităţi de cazare pentru vacanţe şi perioade de scurtă durată having the NACE code 5520.
Sales - Ron
Sales, Profit, Employees, Total Income, Financial Results -
Inga Prima Pharma Srl
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Sales - EUR
14.177
20.619
16.036
29.090
25.539
36.943
37.123
52.404
39.862
40.108
Total Income - EUR
14.194
20.629
16.040
29.090
25.592
37.003
37.128
52.409
40.232
40.692
Total Expenses - EUR
11.700
9.744
7.275
8.002
9.234
9.684
13.911
17.272
31.327
27.935
Gross Profit/Loss - EUR
2.494
10.884
8.765
21.088
16.359
27.319
23.218
35.137
8.905
12.757
Net Profit/Loss - EUR
2.068
10.265
8.284
20.215
15.936
26.363
22.309
34.038
8.551
11.719
Employees
0
0
0
0
0
0
0
1
1
1
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded.
In the last year of activity, the sales increased by 1.2%, from 39.862 euro in the year 2023, to 40.108 euro in 2024.
The Net Profit increased by 3.216 euro, from 8.551 euro in 2023, to 11.719 in the last year.
Check the financial reports for the company - Inga Prima Pharma Srl
Financial Rating - INGA PRIMA PHARMA SRL
See the company's note based on the submitted financial data, relative to the industry of which it is a part.
Financial Rating
Payment Limits - Inga Prima Pharma Srl
See the company's payment capacity for situations in which you conclude contracts with payment terms.
Check Payment Limits
Prob. of insolvency - Inga Prima Pharma Srl
It determines the risk of insolvency based on the submitted accounting balance.
Insolvency Probability
Financial Reports - Inga Prima Pharma Srl
Check all the financial reports of the company and know the risks in collaboration with it.
Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
Debts, Equity, Inventories, Receivables, Accounts, Assets -
Inga Prima Pharma Srl - CUI 28111360
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Fixed Assets
1.826
3.881
2.728
12.603
1.156
662
259
939
1.293
1.385
Current Assets
6.766
8.450
5.613
15.843
14.961
30.726
25.337
34.840
12.489
19.396
Inventories
0
0
0
0
0
0
0
0
0
0
Receivables
0
0
0
0
84
0
0
32.775
408
628
Cash
6.766
8.450
5.613
15.843
14.877
30.726
25.337
2.064
12.081
18.768
Shareholders Funds
6.899
10.319
8.337
28.399
15.987
31.166
22.357
34.086
10.188
17.611
Social Capital
45
45
44
43
42
41
40
41
40
40
Debts
1.694
2.013
4
4
67
181
290
1.693
3.638
3.214
Income in Advance
0
0
0
43
63
41
2.948
0
0
0
Exchange rate - RON
4.9743
4.9465
4.9315
4.9468
4.8371
4.7454
4.6535
4.5681
4.4908
4.445
Main CAEN
"5520 - 5520"
CAEN Financial Year
5520
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
19.396 euro in 2024 which includes Inventories of
0 euro, Receivables of
628 euro and cash availability of
18.768 euro.
The company's Equity was valued at
17.611 euro, while total Liabilities amounted to
3.214 euro.
Equity increased by 7.480 euro, from 10.188 euro in 2023, to 17.611 in 2024.
Similar services useful for checking companies and business development.
SellNet
Get the contact details for any company and get in touch with it.
Sectoral Studies
Knows the market and develops its own development strategies according to sectorial data.
Databases
Export in excel files the data of the companies selected according to the desired criteria.
Import - Export
Find importers and exporters according to the type of activity and the countries in which they carry it out.
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - Inga Prima Pharma Srl